Adverse Event Reporting

Common, generally mild side effects include: injection site reactions (redness, swelling, itching, mild bruising), headache in the first few days of use, mild nausea (especially with GLP-1 agonists), temporary water retention, flushing or warmth (with melanocortin peptides), fatigue or dizziness during titration, and increased hunger (with ghrelin-mimetic GHRPs like GHRP-6).

These mild effects typically resolve within the first 1-2 weeks as the body adjusts, or with dose reduction. They do not usually require discontinuation.

Serious adverse effects that require medical evaluation include: persistent or worsening injection site infections, severe nausea, vomiting, or abdominal pain (especially with GLP-1 agonists — may indicate pancreatitis), significant edema (swelling) in extremities, joint pain or carpal tunnel symptoms (from GH elevation), vision changes, heart palpitations or chest pain, signs of hypoglycemia (shakiness, sweating, confusion, fainting), and jaundice (yellowing of skin or eyes).

Injection site reactions are localized to the injection area and include redness, swelling, pain, itching, and bruising. Most resolve within 24-48 hours. Persistent or spreading reactions (red streaking, increasing warmth, pus) may indicate infection and require medical attention.

Systemic reactions affect the body beyond the injection site. These include generalized skin reactions (hives, rash), cardiovascular effects (blood pressure changes, heart rate changes), gastrointestinal effects (nausea, vomiting, diarrhea), neurological effects (headache, dizziness, vision changes), and metabolic effects (blood sugar changes, fluid retention).

The timing of reactions provides diagnostic information: immediate reactions (within minutes) suggest allergic or hypersensitivity responses; delayed reactions (hours to days) are more commonly pharmacological effects of the peptide; and very delayed reactions (weeks) may indicate cumulative effects or immune-mediated responses.

Call emergency services (911 in the US) immediately for: difficulty breathing or swallowing, throat tightness or swelling, rapid or irregular heartbeat with chest pain, loss of consciousness, severe allergic reaction (anaphylaxis), signs of stroke (sudden numbness, confusion, trouble speaking or seeing).

Seek urgent medical care (urgent care or ER) for: severe abdominal pain (pancreatitis risk with GLP-1 agonists), high fever with injection site infection, severe hypoglycemia not responding to glucose intake, significant unexplained swelling, severe headache with vision changes.

Schedule a medical appointment for: persistent mild side effects that don't resolve with dose reduction, unexpected lab value changes on follow-up bloodwork, any new or unusual symptom that appears during a peptide protocol.

Thorough documentation of adverse events protects your health and contributes to the safety knowledge base. Record: the date and time the reaction began, the peptide name, dose, and route of administration, a detailed description of symptoms (location, severity, duration), any actions taken (dose reduction, discontinuation, medical treatment), and the outcome (resolved, ongoing, worsened).

Include context that may be relevant: whether this was a new peptide or a dose change, concurrent medications or supplements, recent diet or lifestyle changes, any other compounds used in the same timeframe.

Take photographs of visible reactions (injection site reactions, rashes, swelling) with timestamps. Visual documentation is invaluable for medical providers assessing the situation.

The FDA's MedWatch program accepts voluntary reports of adverse events from consumers and healthcare professionals. Reporting helps the FDA identify safety signals and protect public health.

You can submit a MedWatch report online at www.fda.gov/medwatch, by phone at 1-800-FDA-1088, or by downloading and mailing FDA Form 3500. Reports can be submitted anonymously.

When filing a MedWatch report, include: the product name and manufacturer (if known), the lot number (if available), a description of the adverse event, the date it occurred, any medical treatment received, and the outcome.

Even if you are unsure whether an adverse event is related to a peptide, report it. The FDA uses aggregate data to identify patterns that may not be apparent from individual cases.